Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas VP-Business Development Masaki Doi: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

"The Pink Sheet" DAILY visited recently with Astellas Pharma VP-Business Development Masaki Doi at the company's headquarters in Tokyo to talk about the Japanese pharma's global licensing strategy and the changing paradigm of Japanese deal flow.

You may also be interested in...



Death Reported In Phase II Trial For Astellas/FibroGen's Oral EPO Candidate

Astellas/FibroGen have observed one fatality in a Phase II trial of the oral anemia treatment candidate FG-2216, Astellas reported May 7. The cause of death was fulminant hepatitis, and FDA has been notified

Death Reported In Phase II Trial For Astellas/FibroGen's Oral EPO Candidate

Astellas/FibroGen have observed one fatality in a Phase II trial of the oral anemia treatment candidate FG-2216, Astellas reported May 7. The cause of death was fulminant hepatitis, and FDA has been notified

Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head

But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.

Latest News
See All
UsernamePublicRestriction

Register

SC066035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel